{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:16:57Z","timestamp":1772518617564,"version":"3.50.1"},"reference-count":29,"publisher":"FapUNIFESP (SciELO)","issue":"9B","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:p>Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the CNS caused by reactivation of JC virus (JCV) in a setting of cellular immunosuppression. Originally, PML was observed in patients with advanced HIV infection, lymphoproliferative disorders and transplant recipients. However, the widespread use of HIV antiretroviral drugs and the new selective immunomodulatory and immunosuppressive medications, such as Rituximab and Natalizumab, has recently modified the epidemiology, clinical presentation and prognosis of PML. Herein, we discuss the new concepts on PML, emphasizing the recent modification in the epidemiology; the impact of new immunomodulatory treatments in the disease, PML-IRIS (Immune reconstitution inflammatory s\u00edndrome), new treatment strategies and other JCV related CNS diseases.<\/jats:p>","DOI":"10.1590\/0004-282x20130154","type":"journal-article","created":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T13:11:57Z","timestamp":1383052317000},"page":"699-702","source":"Crossref","is-referenced-by-count":20,"title":["Progressive multifocal leukoencephalopathy: new concepts"],"prefix":"10.1590","volume":"71","author":[{"given":"Marco A.","family":"Lima","sequence":"first","affiliation":[{"name":"FIOCRUZ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan CS","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"839719","DOI":"10.1155\/2013\/839719","article-title":"New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy","volume":"2013","author":"Bellizzi A","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy MW","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","article-title":"Progressive multifocal leukoencephalopathy","volume":"2","author":"Brooks BR","year":"1984","journal-title":"Neurol Clin"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","article-title":"Progressive multifocal leukoencephalopathy in patients with HIV infection","volume":"4","author":"Berger JR","year":"1998","journal-title":"J Neurovirol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/598335","article-title":"Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study","volume":"48","author":"Khanna N","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"(Suppl 2)","key":"ref7","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1080\/13550280290101094","article-title":"The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy","volume":"8","author":"Sacktor N","year":"2002","journal-title":"J Neurovirol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy","volume":"127","author":"Du Pasquier RA","year":"2004","journal-title":"Brain"},{"key":"ref9","first-page":"811288","article-title":"Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy","volume":"2010","author":"Lima MA","journal-title":"J Neurol Neurosurg Psych"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2377-12-121","article-title":"Characteristics of progressive multifocal leukoencephalopathy clarified through internet-assisted laboratory surveillance in Japan","volume":"12","author":"Nakamichi K","year":"2012","journal-title":"BMC Neurol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes R","year":"2013","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.V99.4.1486","article-title":"Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab","volume":"99","author":"Goldberg SL","year":"2002","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould A","year":"2005","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche G","year":"2005","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jaad.2010.05.033","article-title":"Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients","volume":"65","author":"Kothary N","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"ref16","first-page":"172","article-title":"Natalizumab: bench to bedside and beyond","volume":"70","author":"Rudick R","year":"2013","journal-title":"AMA Neurol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"loomgren G","year":"2012","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford DB","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","article-title":"Treatment of progressive multifocal leukoencephalopathy associated with natalizumab","volume":"361","author":"Wenning W","year":"2009","journal-title":"N Engl J Med"},{"key":"ref20","article-title":"Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients","author":"Dahlhaus S","year":"2013","journal-title":"J Neurol Neurosurg Psych"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","article-title":"PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids","volume":"72","author":"Tan K","year":"2009","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1413-8670(12)70297-0","article-title":"JC virus-associated central nervous system diseases in HIV-infected patients in Brazil: clinical presentations, associated factors with mortality and outcome","volume":"16","author":"Piza F","year":"2012","journal-title":"Braz J Iinfect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","article-title":"Determinants of survival in progressive multifocal leukoencephalopathy","volume":"73","author":"Marzocchetti A","year":"2009","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneurol.2008.557","article-title":"Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy","volume":"66","author":"Cettomai D","year":"2009","journal-title":"Arch Neurol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/hiv.12008","article-title":"Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score?","volume":"14","author":"Fanjul F","year":"2013","journal-title":"HIV Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e20967","DOI":"10.1371\/journal.pone.0020967","article-title":"Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy","volume":"6","author":"Gasnault J","year":"2011","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ana.20431","article-title":"JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy","volume":"57","author":"Koralnik IJ","year":"2005","journal-title":"Ann Neurol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1191\/0961203305lu2229cr","article-title":"JC virus meningitis in a patient with systemic lupus erythematosus","volume":"14","author":"Viallard JF","year":"2005","journal-title":"Lupus"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e35793","DOI":"10.1371\/journal.pone.0035793","article-title":"JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant","volume":"7","author":"Dang X","year":"2012","journal-title":"PLoS One"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v71n9b\/0004-282X-anp-71-09b-699.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T08:52:45Z","timestamp":1564563165000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2013001000699&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":29,"journal-issue":{"issue":"9B","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0004-282X2013001000699"],"URL":"https:\/\/doi.org\/10.1590\/0004-282x20130154","relation":{},"ISSN":["0004-282X"],"issn-type":[{"value":"0004-282X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}